*AbbVie, InterMune say they defending business secrets. The decision leaves in limbo a high-profile fight that has pitched the European Medicines Agency, Europe's equivalent of the U.S. Food and Drug Administration, against AbbVie and InterMune.» Read More
Earnings blowouts and encouraging drug trials were some of the catalysts behind Thursday's most actively traded stocks.
Hey folks, time for the day's trivia questions. Here they are. The video question is worth $2,000 Bonus Bucks: According to this morning’s report, China’s first quarter GDP was up how much? The selection of answers are: 5.7% or 8.5% or 10.2% or 11.1%. The news trivia question is worth $1,000 Bonus Bucks: Merck reported that revenue climbed from the same quarter last year, boosted in part by sales of what cholesterol drug? The selection of answers are: Lipitor or Plavix or Zetia or Remicade.
It was a volatile day for the celebs. Champion poker player Chris Moneymaker holds onto the first spot despite his $90K loss on Syntel but actor Jonathan Tucker takes over the #2 spot. Meanwhile, Willie Garson falls into 4th, allowing Stephen Collins to gain 3rd place. Johnny Bench falls from 6th to 8th. One of the stocks for Chris M., CBST, is also a favorite of Parker Robinson in our non-celeb trading. Both are "banking" on it paying off.
Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to robust sales of cholesterol drugs and allergy treatments.
Wyeth said quarterly earnings rose a better-than-expected 12% on strong sales of its vaccine against childhood infections, and reported positive trial results for its most important experimental drug.
Merck said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.
Good morning all. Serge Amelyan maintains his lead for the second day running, and Parker Robinson holds 2nd place--as both gain substantially with the top trade of the day on Linear Technology. It was was up 12.20% Wednesday on strong earnings. AND Serge is the first contestant to break the $3M mark with a total portfolio value of $3,236,223.05 up $351,671.04 from Tuesday's total on the sale of Linear Technology.
Gilead Sciences said on Wednesday its first-quarter profit rose 55% amid higher sales of its drugs for HIV, the virus that causes AIDS.
Abbott Laboratories said on Wednesday its first-quarter earnings fell 19% as charges related to acquisitions and cost-cutting offset sharply higher sales of its prescription drugs and medical devices.
Hey folks--we have guest blogger Jeff Mishlove's contest picks for the day. Let's get right to his comments: Now that the Tuesday results are in, I see that my top recommendation for Monday had a significant price gain. That was Adtran, Inc., which rose 6.16%. This stock had a lot going for it: it was favored by hedge funds and professional investors; it was approaching its 52-week high; a significant amount of stock was controlled by short sellers..
Fast-selling cancer drugs boosted first-quarter sales at Roche Holding by 16% to 11.4 billion Swiss francs ($9.41 billion), the Swiss drugmaker said, raising its outlook for the full year.
Should the government be allowed to negotiate Medicare drug prices? Two health-policy experts joined "Power Lunch" to debate whether Federal influence will damage the free market -- or if the current ban on government negotiations hurts the consumer more.
Merck and GlaxoSmithKline both released news about their respective treatments for human papillomavirus Tuesday, leaving them "duking it out over what's expected to be the multi-billion dollar HPV cervical cancer vaccine market," reported CNBC's Mike Huckman.
Johnson & Johnson beat the Street and raised its outlook for this year, but the hybrid Pharma/Consumer Products/Medical Devices company posted a much bigger drop in sales of its highly profitable drug-coated stents than analysts expected. Stents are the expensive, little wire mesh tubes that prop open clogged arteries. Recently, sales of stents coated with drugs have come under increasing scrutiny over safety.
Blogger Timothy Sykes is back with his contest picks. Here's his post: I hope everyone tuned in Friday to witness me becoming the first guest to bring female models on CNBC to show off the beauty of stock charts. The audience and the other studio guests loved it so hopefully I’ve started a new trend. We’ll see…This week’s picks are (in order of importance)...
Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.
We have more video from Friday night's contest program, "How To Win." Specifically, more stock picks from our guest analysts. One of them, Timothy Sykes, who is also a guest blogger, loves the charts as you'll hear him explain. He also explains, his picks could have an upside, as well as a down side. So it's buyer beware for sure (fyi--it's that way with all the picks!).
Pharmaceutical maker Shire said Monday that its shareholders approved the proposed acquisition of New River Pharmaceuticals.
Drug maker Eli Lilly reported first-quarter earnings and sales ahead of market expectations Monday and also boosted guidance for the year, thanks to strong sales of drugs for schizophrenia and depression.
Here's our look at contest stocks from Thursday's close to Friday's close. Old stand by Freemont General brought owners/sellers some new gains. The most active and widely held stocks remained pretty much the same as they have been. One of the best performers Cott, was up on consolidation news involving Cadbury. Here's the breakdown: